Click for best price
NonAlcoholic Steatohepatitis NASH Therapeutics Diagnostics Market Size, Share 2023
Non-alcoholic steatohepatitis (NASH), also known as non-alcoholic fatty liver disease (NAFLD), is a disease caused by excessive accumulation of fat in the liver.
This report aims to provide a comprehensive presentation of the global market for Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics. This report contains market size and forecasts of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics in global, including the following market information:
Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Therapeutics Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics include Siemens Healthcare, Celerion, ZyVersa Therapeutics, Inc., Cisbio, Regeneron Pharmaceuticals, Inc., BioPredictive, Echosens, Genfit and Enterome, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Segment Percentages, by Type, 2022 (%)
Therapeutics
Diagnostics
Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Siemens Healthcare
Celerion
ZyVersa Therapeutics, Inc.
Cisbio
Regeneron Pharmaceuticals, Inc.
BioPredictive
Echosens
Genfit
Enterome
NGM Biopharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics, market overview.
Chapter 2: Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market size in revenue.
Chapter 3: Detailed analysis of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, Global Outlook and Forecast 2023-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
61 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Overall Market Size
2.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size: 2022 VS 2030
2.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players in Global Market
3.2 Top Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Companies Ranked by Revenue
3.3 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players in Global Market
3.6.1 List of Global Tier 1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Markets, 2022 & 2030
4.1.2 Therapeutics
4.1.3 Diagnostics
4.2 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue & Forecasts
4.2.1 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, 2018-2023
4.2.2 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, 2024-2030
4.2.3 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2022 & 2030
5.1.2 Hospital
5.1.3 Clinic
5.2 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue & Forecasts
5.2.1 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, 2018-2023
5.2.2 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, 2024-2030
5.2.3 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2022 & 2030
6.2 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue & Forecasts
6.2.1 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, 2018-2023
6.2.2 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, 2024-2030
6.2.3 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, 2018-2030
6.3.2 US Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.3.3 Canada Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.3.4 Mexico Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, 2018-2030
6.4.2 Germany Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.4.3 France Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.4.4 U.K. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.4.5 Italy Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.4.6 Russia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.4.7 Nordic Countries Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.4.8 Benelux Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, 2018-2030
6.5.2 China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.5.3 Japan Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.5.4 South Korea Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.5.5 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.5.6 India Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, 2018-2030
6.6.2 Brazil Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.6.3 Argentina Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, 2018-2030
6.7.2 Turkey Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.7.3 Israel Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.7.4 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.7.5 UAE Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
7 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Companies Profiles
7.1 Siemens Healthcare
7.1.1 Siemens Healthcare Company Summary
7.1.2 Siemens Healthcare Business Overview
7.1.3 Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Major Product Offerings
7.1.4 Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global Market (2018-2023)
7.1.5 Siemens Healthcare Key News & Latest Developments
7.2 Celerion
7.2.1 Celerion Company Summary
7.2.2 Celerion Business Overview
7.2.3 Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Major Product Offerings
7.2.4 Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global Market (2018-2023)
7.2.5 Celerion Key News & Latest Developments
7.3 ZyVersa Therapeutics, Inc.
7.3.1 ZyVersa Therapeutics, Inc. Company Summary
7.3.2 ZyVersa Therapeutics, Inc. Business Overview
7.3.3 ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Major Product Offerings
7.3.4 ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global Market (2018-2023)
7.3.5 ZyVersa Therapeutics, Inc. Key News & Latest Developments
7.4 Cisbio
7.4.1 Cisbio Company Summary
7.4.2 Cisbio Business Overview
7.4.3 Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Major Product Offerings
7.4.4 Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global Market (2018-2023)
7.4.5 Cisbio Key News & Latest Developments
7.5 Regeneron Pharmaceuticals, Inc.
7.5.1 Regeneron Pharmaceuticals, Inc. Company Summary
7.5.2 Regeneron Pharmaceuticals, Inc. Business Overview
7.5.3 Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Major Product Offerings
7.5.4 Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global Market (2018-2023)
7.5.5 Regeneron Pharmaceuticals, Inc. Key News & Latest Developments
7.6 BioPredictive
7.6.1 BioPredictive Company Summary
7.6.2 BioPredictive Business Overview
7.6.3 BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Major Product Offerings
7.6.4 BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global Market (2018-2023)
7.6.5 BioPredictive Key News & Latest Developments
7.7 Echosens
7.7.1 Echosens Company Summary
7.7.2 Echosens Business Overview
7.7.3 Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Major Product Offerings
7.7.4 Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global Market (2018-2023)
7.7.5 Echosens Key News & Latest Developments
7.8 Genfit
7.8.1 Genfit Company Summary
7.8.2 Genfit Business Overview
7.8.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Major Product Offerings
7.8.4 Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global Market (2018-2023)
7.8.5 Genfit Key News & Latest Developments
7.9 Enterome
7.9.1 Enterome Company Summary
7.9.2 Enterome Business Overview
7.9.3 Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Major Product Offerings
7.9.4 Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global Market (2018-2023)
7.9.5 Enterome Key News & Latest Developments
7.10 NGM Biopharmaceuticals
7.10.1 NGM Biopharmaceuticals Company Summary
7.10.2 NGM Biopharmaceuticals Business Overview
7.10.3 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Major Product Offerings
7.10.4 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global Market (2018-2023)
7.10.5 NGM Biopharmaceuticals Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Opportunities & Trends in Global Market
Table 2. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Drivers in Global Market
Table 3. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Restraints in Global Market
Table 4. Key Players of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics in Global Market
Table 5. Top Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Share by Companies, 2018-2023
Table 8. Global Companies Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Type
Table 9. List of Global Tier 1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2024-2030
Table 30. Siemens Healthcare Company Summary
Table 31. Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offerings
Table 32. Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 33. Siemens Healthcare Key News & Latest Developments
Table 34. Celerion Company Summary
Table 35. Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offerings
Table 36. Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 37. Celerion Key News & Latest Developments
Table 38. ZyVersa Therapeutics, Inc. Company Summary
Table 39. ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offerings
Table 40. ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 41. ZyVersa Therapeutics, Inc. Key News & Latest Developments
Table 42. Cisbio Company Summary
Table 43. Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offerings
Table 44. Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 45. Cisbio Key News & Latest Developments
Table 46. Regeneron Pharmaceuticals, Inc. Company Summary
Table 47. Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offerings
Table 48. Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 49. Regeneron Pharmaceuticals, Inc. Key News & Latest Developments
Table 50. BioPredictive Company Summary
Table 51. BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offerings
Table 52. BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 53. BioPredictive Key News & Latest Developments
Table 54. Echosens Company Summary
Table 55. Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offerings
Table 56. Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 57. Echosens Key News & Latest Developments
Table 58. Genfit Company Summary
Table 59. Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offerings
Table 60. Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 61. Genfit Key News & Latest Developments
Table 62. Enterome Company Summary
Table 63. Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offerings
Table 64. Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 65. Enterome Key News & Latest Developments
Table 66. NGM Biopharmaceuticals Company Summary
Table 67. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offerings
Table 68. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 69. NGM Biopharmaceuticals Key News & Latest Developments
List of Figures
Figure 1. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Segment by Type in 2022
Figure 2. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Segment by Application in 2022
Figure 3. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in 2022
Figure 8. By Type - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
Figure 9. By Application - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
Figure 10. By Type - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
Figure 12. By Application - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
Figure 14. By Region - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
Figure 15. By Country - North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
Figure 16. US Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
Figure 20. Germany Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 21. France Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
Figure 28. China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 32. India Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
Figure 34. Brazil Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
Figure 37. Turkey Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 41. Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
